1,777 Shares in Zoetis Inc. (NYSE:ZTS) Bought by Stanley Laman Group Ltd.

Stanley Laman Group Ltd. purchased a new position in shares of Zoetis Inc. (NYSE:ZTS) during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission. The firm purchased 1,777 shares of the company’s stock, valued at approximately $293,000.

Other hedge funds and other institutional investors also recently bought and sold shares of the company. Callahan Advisors LLC grew its position in Zoetis by 90.4% during the 4th quarter. Callahan Advisors LLC now owns 13,105 shares of the company’s stock worth $2,135,000 after purchasing an additional 6,221 shares during the last quarter. CIBC Asset Management Inc grew its position in Zoetis by 24.1% during the 4th quarter. CIBC Asset Management Inc now owns 237,369 shares of the company’s stock worth $38,617,000 after purchasing an additional 46,050 shares during the last quarter. Schroder Investment Management Group grew its position in Zoetis by 2.6% during the 4th quarter. Schroder Investment Management Group now owns 245,726 shares of the company’s stock worth $40,036,000 after purchasing an additional 6,169 shares during the last quarter. Vanguard Group Inc. grew its position in Zoetis by 0.3% during the 4th quarter. Vanguard Group Inc. now owns 41,366,877 shares of the company’s stock worth $6,739,905,000 after purchasing an additional 120,158 shares during the last quarter. Finally, Portside Wealth Group LLC boosted its holdings in shares of Zoetis by 24.7% in the first quarter. Portside Wealth Group LLC now owns 33,709 shares of the company’s stock valued at $5,550,000 after acquiring an additional 6,672 shares in the last quarter. 92.80% of the stock is owned by hedge funds and other institutional investors.

Zoetis Stock Down 2.7%

ZTS stock opened at $164.27 on Friday. The company has a market cap of $73.13 billion, a P/E ratio of 30.03, a P/E/G ratio of 2.78 and a beta of 0.94. Zoetis Inc. has a 52 week low of $139.70 and a 52 week high of $200.33. The company’s 50-day moving average price is $158.67 and its 200 day moving average price is $164.01. The company has a current ratio of 1.75, a quick ratio of 1.08 and a debt-to-equity ratio of 1.09.

Zoetis (NYSE:ZTS) last released its quarterly earnings data on Tuesday, May 6th. The company reported $1.48 EPS for the quarter, topping analysts’ consensus estimates of $1.40 by $0.08. The firm had revenue of $2.22 billion for the quarter, compared to the consensus estimate of $2.20 billion. Zoetis had a net margin of 26.86% and a return on equity of 53.82%. The firm’s revenue was up 1.4% on a year-over-year basis. During the same quarter in the previous year, the firm earned $1.38 earnings per share. On average, research analysts expect that Zoetis Inc. will post 6.07 earnings per share for the current fiscal year.

Zoetis Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Wednesday, September 3rd. Shareholders of record on Friday, July 18th will be given a dividend of $0.50 per share. This represents a $2.00 dividend on an annualized basis and a yield of 1.22%. The ex-dividend date of this dividend is Friday, July 18th. Zoetis’s payout ratio is currently 35.91%.

Wall Street Analyst Weigh In

ZTS has been the topic of several analyst reports. Stifel Nicolaus lowered their target price on shares of Zoetis from $180.00 to $165.00 and set a “buy” rating on the stock in a report on Monday, April 14th. Wall Street Zen raised shares of Zoetis from a “hold” rating to a “buy” rating in a report on Friday, March 7th. UBS Group lowered their target price on shares of Zoetis from $189.00 to $170.00 and set a “neutral” rating on the stock in a report on Wednesday, May 7th. Morgan Stanley lowered their target price on shares of Zoetis from $243.00 to $238.00 and set an “overweight” rating on the stock in a report on Friday, February 14th. Finally, Piper Sandler lifted their target price on shares of Zoetis from $205.00 to $210.00 and gave the company an “overweight” rating in a report on Monday, May 12th. One analyst has rated the stock with a hold rating, eight have assigned a buy rating and two have given a strong buy rating to the stock. According to MarketBeat.com, Zoetis has a consensus rating of “Buy” and an average price target of $212.75.

Insiders Place Their Bets

In other Zoetis news, EVP Roxanne Lagano sold 652 shares of Zoetis stock in a transaction dated Tuesday, June 3rd. The shares were sold at an average price of $170.00, for a total transaction of $110,840.00. Following the completion of the transaction, the executive vice president now owns 15,129 shares in the company, valued at approximately $2,571,930. The trade was a 4.13% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. 0.18% of the stock is currently owned by company insiders.

About Zoetis

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.